Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Bank of America Securities, maintained a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), while setting a price target of $7. In line with the consensus 1-year median price target, the stock boasts an upside potential of 51.84%. On the same day, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) disclosed a revised investor presentation ahead of its use at the JP Morgan Healthcare Conference. The presentation highlighted developments in its three core areas: AI-powered drug discovery platform, clinical pipeline, and financial environment. The company outlined its pioneer AI-driven clinical proof-of-concept in familial adenomatous polyposis (REC-4881), offering nearly 15 discovery-stage assets, and milestones with collaborators, including Sanofi, Roche and Genentech. wavebreakmedia/Shutterstock.com Additionally, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) recorded $755 million in unaudited year-end 2025 cash position, anticipating cash runway through the end of 2027. Th
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural ShiftPR Newswire
- Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 1/22/26 - Form 4
- 1/20/26 - Form 144
- 1/12/26 - Form 8-K
- RXRX's page on the SEC website